Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD

Aliverti, A.; Dellacà, R. L.; Mauro, A. Lo; Pedotti, A.; Rodger, K.; Stevenson, N.; Calverley, P. M. A.
November 2005
Thorax;Nov2005, Vol. 60 Issue 11, p916
Academic Journal
Background: Inhaled bronchodilators can increase exercise capacity in chronic obstructive pulmonary disease (COPD) by reducing dynamic hyperinflation, but treatment is not always effective. This may reflect the degree to which the abdomen allows dynamic hyperinflation to occur. Method: A double blind, randomised, crossover trial of the effect of 5 mg nebulised salbutamol or saline on endurance exercise time was conducted in 18 patients with COPD of mean (SD) age 67.1(6.3) years and mean (SD) forced expiratory volume in 1 second (FEV1) of 40.6 (1 5.0)% predicted. Breathing pattern, metabolic variables, dyspnoea intensity, and total and regional chest wall volumes were measured non-invasively by optoelectronic plethysmography (OEP) at rest and during exercise. Results: Salbutamol increased FEV1, forced vital capacity (FVC) and inspiratory capacity and reduced functional residual capacity (FRC) and residual volume significantly. OEP showed the change in resting FRC to be mainly in the abdominal compartment. Although the mean (SE) end expiratory chest wall volume was 541 (118) ml lower (p<0.001) at the end of exercise, the endurance time was unchanged by the bronchodilator. Changes in resting lung volumes were smaller when exercise duration did not improve, but FEV1 still rose significantly after active drug. After the bronchodilator these patients tried to reduce the end expiratory lung volume when exercising, while those exercising longer continued to allow end expiratory abdominal wall volume to rise. The change to a more euvolumic breathing pattern was associated with a lower oxygen pulse and a significant fall in endurance time with higher isotime levels of dyspnoea. Conclusions: Nebulised salbutamol improved forced expiratory flow in most patients with COPD, but less hyperinflated patients tried to reduce the abdominal compartmental volume after active treatment and this reduced their exercise capacity. Identifying these patients has important therapeutic implications, as does an understanding of the mechanisms that control chest wall muscle recruitment.


Related Articles

  • Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Tashkin, Donald P.; Fabbri, Leonardo M. // Respiratory Research;2010, Vol. 11, p149 

    Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long-acting bronchodilators are the mainstay of therapy; as symptoms progress, guidelines recommend combining bronchodilators from...

  • Synergetic interactions between rehabilitation and pharmacotherapy in COPD. Pepin, Véronique; Laviolette, Louis; Saey, Didier; Maltais, François // Clinical & Investigative Medicine;Jun2006, Vol. 29 Issue 3, p170 

    Background. Once viewed as an irreversible condition, chronic obstructive pulmonary disease (COPD) is now considered as a preventable and treatable disease. The past ten years of research have clearly indicate that dyspnea, exercise tolerance and quality of life can be improved considerably with...

  • Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.  // Current Medical Literature: Respiratory Medicine;2008, Vol. 22 Issue 3, p79 

    The article discusses research being done on the use of nebulized formoterol in patients with chronic obstructive pulmonary disease (COPD) taking tiotropium. Results showed that both forced expiratory volume and dyspnea have improved following the addition of formoterol. However, the study found...

  • Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. O'Donnell, D. E.; Laveneziana, P.; Ora, J.; Webb, K. A.; Lam, Y.-M.; Ofir, D. // Thorax;Mar2009, Vol. 64 Issue 3, p216 

    BACKGROUND: Patients with symptoms of GOLD stage I chronic obstructive pulmonary disease (COPD) can have significant abnormalities of ventilatory mechanics with greater exertional symptoms and exercise limitation than age-matched healthy subjects. In such patients the impact of bronchodilator...

  • Altering the Course of Disease Is Crucial in COPD. Dziedzic, Jessica // Pulmonary Reviews;Sep2008, Vol. 13 Issue 9, p1 

    The article discusses the treatment for Chronic Obstructive Pulmonary Disease (COPD). It states that correcting lung hyperinflation, reducing the frequency and severity of exacerbations, and preventing lung function decline can treat the symptoms and alter the COPD progression. Dr. Marc...

  • Deflazacort/methylprednisolone.  // Reactions Weekly;12/1/2007, Issue 1180, p13 

    The article describes the case of three chronic obstructive pulmonary disease (COPD) patients who developed pulmonary aspergillosis caused by Aspergillus terreus during treatment with deflazacort and methylprednisolone or methylprednisolone alone. The first patient was hospitalized d with...

  • Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Hadcroft, J.; Calverley, P. M. A. // Thorax;Sep2001, Vol. 56 Issue 9, p713 

    Background-Bronchodilator reversibility testing is recommended in all patients with chronic obstructive pulmonary disease (COPD) but does not predict improvements in breathlessness or exercise performance. Two alternative ways of assessing lung mechanics-measurement of end expiratory lung volume...

  • Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD. Peters, M. M.; A.^ Webb, K.; O'Donnell, D. E. // Thorax;Jul2006, Vol. 61 Issue 7, p559 

    Background: Studies examining the physiological interactions of oxygen (O2) and bronchodilators (BD) during exercise in chronic obstructive pulmonary disease (COPD) should provide new insights into mechanisms of exercise intolerance. We examined the effects of O2 and BD, alone and in...

  • Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care. Suresh Punekar, Yogesh; Landis, Sarah H.; Wurst, Keele; Hoa Le; Punekar, Yogesh Suresh; Le, Hoa // Respiratory Research;11/16/2015, Vol. 16 Issue 1, p1 

    Background: To assess the symptomatic and cost burden among patients initiating long-acting bronchodilator (LABD) therapy and impact of adherence on healthcare resource use and costs.Methods: This retrospective cohort study identified patients with COPD who were newly...


Read the Article


Sign out of this library

Other Topics